Table 4.
Published studies on the treatment of HCC with PVTT with yttrium-90.
| Study (author/year/microspheres type/reference) |
PVTT population/total population |
6-month survival (%) | Disease Control rate at X months (%) |
Median OS (months) |
Median PFS (months) |
|---|---|---|---|---|---|
| Salem et al., 2004: glass [15] | n = 15/15 | 53 | — | 7.1 (4.1–13.9) |
— |
| Woodall et al., 2009: glass [18] | n = 15/52 | — | — | 3.2 | — |
| Kulik et al., 2008: glass [14] | n = 37/108 | — | — |
Branch
PVTT: 9.9 (7.1–15.7) Main PVTT: 4.4 (2.9–7.4) |
— |
| Tsai et al., 2010: glass and resin [17] |
n = 22/22 15 evaluable |
— | 2-3 months: 58 (RECIST) | 7.0 | — |
|
Iñarrairaegui et al., 2010: resin [13] |
n = 25/25 | 64 | 2 months: 66.7 and 6 months: 50 (RECIST) |
10.0 (6.6–13.3) |
— |
|
Hilgard et al., 2010: glass [12] |
n = 33/108 | 65 (95% CI 46–92%) |
3 months: 90 (RECIST) 94 (EASL) | 10.0 (6.0–∞) | 8.0 (5.9–∞) |
| Salem et al., 2010: glass [16] |
n = 92/291 (35 Child A and 57 Child B) |
— | 2-3 months: 50 Child A
and 32 Child B (EASL) |
10.4 (7.2–16.6) Child A
5.6 (4.5–6.7) Child B |
5.6 (2.3–7.6) Child A
5.9 (4.2–7.9) Child B |
|
Sangro et al., 2011: resin [24] |
n = 76/325 (branch + main) |
— | 3 months: 88.9% (EASL) | 10.2 (7.7–11.8) |
— |
|
Mazzaferro et al., 2012: glass [25] |
n = 35/52 (branch + main) |
— | 3 months: 74.3 (EASL) | 13.0 (9.0–17.0) |
7.0 (6.0–12.0) |